The WHO last week announced plans to explore options for prequalifying insulin a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drug. The WHO is considering whether to extend the prequalification process to manufacturers creating me too versions of insulin more commonly known as biosimilars.